The feared thing keeps not happening: management confronts a specific live worry with current evidence running against i
The model's full reasoning — Q3 2016 call → NOWe need to determine if there is a specific negative outcome that investors/analysts/market are worried about, and if management pushes back with current observed evidence. Let's analyze the transcript. The call covers various programs. Analysts ask questions about enrollment in SOPHIA, MGD011, MGD006, MGD007, etc. There is no explicit mention of a specific fear like "demand will fall off" or "partner will leave" etc. However, there is a question about MGD011 (CD19 x CD3) which was placed on clinical hold by FDA? Actually, the analyst asks about a study listed as suspended on clinicaltrials.gov. Management says it's a study with Janssen, and that they had questions from FDA, but no further update. That's not a fear about MacroGenics' own business? It's about a partner's study. Management doesn't push back with evidence; they just say no update. Another question about MGD006 and the J&J hold on a similar molecule. Management says they continue enrolling, no indication of impact. That's a potential fear that a competitor's safety issue might affect their program, but management says no impact so far. Is that a specific fear? Possibly, but management's response is that they are continuing and have no indication. That's not really citing observed evidence of the feared outcome not materializing? They say they continue to enroll patients, which is observed behavior. But is the fear that their program will be halted? They say no indication. That might be a pushback with current evidence (they are enrolling). But is it a "named, company-specific fear" that is live? The analyst asks about it, but management doesn't acknowledge it as a worry others hold. They just answer. Another question about MGD007 (gpA33) - management says they are still early, no update. Not a fear. The question about MGD010 - management says they regained rights, and they have received inbound calls, but no specific fear. The question about SOPHIA enrollment - management says they will provide more detail at R&D day, but no fear. Overall, there is no clear dynamic where analysts are probing a specific negative outcome and management counters with observed evidence.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AVTR | Avantor, Inc. | Q2 2024 | 2024-07-26 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| TYGO | Tigo Energy, Inc. | Q4 2023 | 2024-02-14 | F |
| MET | MetLife, Inc. | Q4 2023 | 2024-02-01 | B+ |
| BBVA | Banco Bilbao Vizcaya Argentaria, S.A. | Q4 2023 | 2024-01-30 | B+ |
| TBLA | Taboola.com Ltd. | Q3 2023 | 2023-11-08 | B+ |
| GMED | Globus Medical, Inc. | Q3 2023 | 2023-11-07 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| MAC | The Macerich Company | Q3 2023 | 2023-10-31 | D |
| LNTH | Lantheus Holdings, Inc. | Q2 2023 | 2023-08-03 | C+ |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| TREX | Trex Company, Inc. | Q2 2023 | 2023-07-31 | B+ |
| REYN | Reynolds Consumer Products Inc. | Q1 2023 | 2023-05-10 | C |
| DOCN | DigitalOcean Holdings, Inc. | Q1 2023 | 2023-05-09 | C+ |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| AKR | Acadia Realty Trust | Q4 2022 | 2023-05-06 | B+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| EPR | EPR Properties | Q1 2023 | 2023-04-27 | C+ |
| MEDP | Medpace Holdings, Inc. | Q1 2023 | 2023-04-25 | B+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| POOL | Pool Corporation | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| REGN | Regeneron Pharmaceuticals, Inc. | Q4 2022 | 2023-02-03 | C |
| HBAN | Huntington Bancshares Incorporated | Q4 2022 | 2023-01-20 | B |
| A | Agilent Technologies, Inc. | Q4 2022 | 2022-11-21 | B+ |
| PCTY | Paylocity Holding Corporation | Q1 2023 | 2022-11-05 | A |
| TT | Trane Technologies plc | Q3 2022 | 2022-11-02 | A |
| APOG | Apogee Enterprises, Inc. | Q2 2023 | 2022-09-20 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| ZBRA | Zebra Technologies Corporation | Q2 2022 | 2022-08-02 | C+ |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| SHW | The Sherwin-Williams Company | Q2 2022 | 2022-07-27 | D |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| DCGO | DocGo Inc. | Q1 2022 | 2022-05-14 | C |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| EGHT | 8x8, Inc. | Q4 2022 | 2022-05-10 | C+ |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| ABNB | Airbnb, Inc. | Q1 2022 | 2022-05-03 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| BSX | Boston Scientific Corporation | Q1 2022 | 2022-04-27 | B |
| CCK | Crown Holdings, Inc. | Q1 2022 | 2022-04-26 | C+ |
| FR | First Industrial Realty Trust, Inc. | Q1 2022 | 2022-04-21 | A |
| SDIG | Stronghold Digital Mining, Inc. | Q3 2021 | 2021-11-30 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| HSY | The Hershey Company | Q3 2021 | 2021-10-28 | C |
| PEP | PepsiCo, Inc. | Q3 2021 | 2021-10-05 | B |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| PTVE | Pactiv Evergreen Inc. | Q2 2021 | 2021-08-08 | C+ |
| SPG | Simon Property Group, Inc. | Q2 2021 | 2021-08-02 | B |
| GLW | Corning Incorporated | Q2 2021 | 2021-07-27 | B+ |
| DOV | Dover Corporation | Q2 2021 | 2021-07-20 | B+ |
| VLRS | Controladora Vuela Compañía de Aviación, | Q2 2021 | 2021-07-16 | B+ |
| MAR | Marriott International, Inc. | Q2 2018 | 2018-08-07 | B |
| VALE | Vale S.A. | Q2 2018 | 2018-07-26 | B |
| FICO | Fair Isaac Corporation | Q3 2018 | 2018-07-26 | C+ |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| TRUE | TrueCar, Inc. | Q1 2018 | 2018-05-08 | C |
| TGNA | TEGNA Inc. | Q1 2018 | 2018-05-08 | B+ |
| CVS | CVS Health Corporation | Q1 2018 | 2018-05-02 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| MIDD | The Middleby Corporation | Q4 2017 | 2018-02-28 | C |
| SBUX | Starbucks Corporation | Q1 2018 | 2018-01-26 | C |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| GURE | Gulf Resources, Inc. | Q3 2017 | 2017-11-14 | F |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BCRX | BioCryst Pharmaceuticals, Inc. | Q1 2017 | 2017-05-07 | B |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| CGNT | Cognyte Software Ltd. | Q4 2016 | 2017-03-09 | D |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| SEM | Select Medical Holdings Corporation | Q1 2016 | 2016-05-06 | C+ |
| LPSN | LivePerson, Inc. | Q1 2016 | 2016-05-04 | B |
| UVE | Universal Insurance Holdings, Inc. | Q1 2016 | 2016-05-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| VRTS | Virtus Investment Partners, Inc. | Q1 2016 | 2016-04-29 | D |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| BX | Blackstone Inc. | Q1 2016 | 2016-04-21 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
TGI · Q2 2017 → YESThe question is: Is there a specific negative outcome that investors/analysts/market are worried about for THIS company, live on this call, and does management push back with CURRENT, ALREADY-OBSERVED...YES The specific, company-attached fear that is live on the call is that Triumph will continue to face large performance-related charges, cash burn on development programs, and failure to stabilize margins/cash flow despite the transformation (a worry analysts repeatedly probe via questions on the $80M risk, free-cash-use guidance, 747-8/C-17/G650 headwinds, and red programs). Management directly counters it by citing already-observed evidence: Q2 operating income of $70.
ULCC · Q1 2023 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors/analysts/market have been worried about for THIS company, live on this call, AND does management push back with CURRENT, ALREADY-OB...YES The transcript shows a live, company-specific worry about pilot staffing shortages (tied to network changes and new contracts elsewhere) and customer churn/retention due to lower satisfaction scores. Management directly counters both with current evidence: pilot surplus and attrition on target for staffing, plus over 90% repeat business for retention.
HOLX · Q4 2017 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company, and does management push back on that worry by poin...YES The transcript shows a live, company-specific fear centered on Cynosure: investors and analysts are worried that the acquisition will not deliver sustainable growth, that recent sequential declines reflect a lasting salesforce collapse or competitive erosion, and that the business will continue underperforming expectations rather than turning around.